

Express Mail Label No. 948639256 US
Date of Deposit: February 6, 2003

Response #19
Priority Docket No. 23135-502

(NOV-2)

2 26 03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Bernard Conrad *et al.*

APPLICATION
NUMBER: 09/490,700

EXAMINER: Natalie A. Davis, Ph.D.

FILING DATE: January 24, 2000

ART UNIT: 1642

FOR: Methods For Diagnosis And Therapy Of Autoimmune Disease, Such As
Insulin Dependent Diabetes Mellitus, Involving Retroviral Superantigens

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

This amendment is in response to the Office Action dated January 29, 2003 (Paper No. 18). No other fee is believed due in connection with this response. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23135-502 (NOV-2.)

Pursuant to 37 CFR 1.121(c)(1)(ii), a marked up version of the claims *as previously amended in Applicants' October 29, 2002 response showing the changes made in that amendment*, appears as Appendix A of this Amendment.

REMARKS

In their Response to Office Action filed October 29, 2002, Applicants amended the claims. Claim 67 was canceled without prejudice or disclaimer, claim was amended, and new claims 77- 79 were added to individually claim the peptides of the invention. However, the marked up version of the claims did not appear to indicate the amendments made.

The attached Appendix A is responsive to the Office Action dated January 29, 2003, and shows the marked-up version of the amended claims, namely the amendment to claim 62, and the addition of claims 77-79.

SUMMARY

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.